Last reviewed · How we verify
Licensed DTPa containing vaccine
Stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins
Stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis toxins Used for Prevention of diphtheria, tetanus, and pertussis.
At a glance
| Generic name | Licensed DTPa containing vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated whole-cell vaccine |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by introducing inactivated toxins from diphtheria, tetanus, and pertussis bacteria to the body, which triggers an immune response and the production of antibodies to fight these infections.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Study to Evaluate GR1801's Efficacy and Safety (PHASE3)
- US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease (PHASE4)
- Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (PHASE2)
- Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (PHASE2)
- Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed DTPa containing vaccine CI brief — competitive landscape report
- Licensed DTPa containing vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI